ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,789.90
0.81%
S&P ASX All Technology
3,074.80
0.36%
Brent Oil
82.15
0.21%
US Dollar vs AUD
1.50725
-0.14%
Bitcoin
68,824.45
0.46%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) News

ARQT Arcutis Biotherapeutics Inc

9.16
0.08 (0.88%)
25 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Arcutis Biotherapeutics Inc ARQT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.08 0.88% 9.16 14:00:05
Open Price Low Price High Price Close Price Previous Close
9.17 8.95 9.355 9.16 9.08
more quote information »

Recent News

Date Time Source Heading
21/5/202407:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/5/202405:58EDGAR2Form 144 - Report of proposed sale of securities
15/5/202406:06EDGAR2Form 8-K - Current report
15/5/202406:00GLOBEArcutis Announces First Quarter 2024 Financial Results and..
14/5/202421:18IHMARKETNEWSUS Futures Remain Steady Amid Wall Street Caution Ahead of..
13/5/202422:00GLOBEExpert Panel Review Further Validates Use of ZORYVE®..
04/5/202406:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
30/4/202406:00GLOBEArcutis to Report First Quarter 2024 Financial Results..
10/4/202422:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
06/4/202407:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/4/202422:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
28/3/202423:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11/3/202423:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
11/3/202407:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
10/3/202408:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
07/3/202409:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202409:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202409:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202408:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
05/3/202409:47EDGAR2Form 144 - Report of proposed sale of securities
05/3/202409:42EDGAR2Form 144 - Report of proposed sale of securities
05/3/202409:40EDGAR2Form 144 - Report of proposed sale of securities
05/3/202408:10EDGAR2Form 8-K - Current report
05/3/202408:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
05/3/202400:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
02/3/202408:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202408:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/3/202409:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
29/2/202415:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
29/2/202408:54EDGAR2Form 144 - Report of proposed sale of securities
29/2/202408:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/2/202408:10EDGAR2Form 8-K - Current report
29/2/202408:10GLOBEArcutis Announces Proposed Public Offering
29/2/202408:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
28/2/202408:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202423:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202423:44EDGAR2Form 8-K - Current report
27/2/202421:50GLOBEArcutis Announces Fourth Quarter and Full Year 2023..
17/2/202400:00GLOBEArcutis to Report Fourth Quarter and Full Year 2023..
16/2/202410:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202410:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202410:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202408:20EDGAR2Form 8-K - Current report
16/2/202408:19EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
14/2/202401:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202416:15EDGAR2Form EFFECT - Notice of Effectiveness
09/2/202408:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/2/202408:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/2/202409:22EDGAR2Form S-3 - Registration statement under Securities Act of..
01/2/202400:00GLOBEArcutis to Present at the Guggenheim Healthcare Talks – 6th..

Your Recent History

NASDAQ
ARQT
Arcutis Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved